Medical University of Innsbruck, Innsbruck, Austria [email protected]
Dr. Deisenhammer reports receiving travel support from Biogen, Sanofi Genzyme, Merck, Novartis Pharma, Roche Pharma, and Teva Ratiopharm, consulting fees from Biogen, Sanofi Genzyme, Merck, Novartis Pharma, and Roche Pharma, and speaking fees from Biogen, Sanofi Genzyme, and Novartis Pharmaceuticals; Dr. Auer, receiving speaking fees from Novartis Pharma and travel funding from Biogen Idec; and Dr. Hegen, receiving speaking fees from Bayer, Biogen, and Merck, travel funding from Bayer, Biogen, and Novartis Pharma, and consulting fees from Teva Pharmaceuticals Europe. No other potential conflict of interest relevant to this letter was reported.
